|
| Friday, 6 March 2015, 05:45 HKT/SGT | |
| |  | |
Source: Omnicare | |
|
|
|
CINCINNATI, OH, Mar 6, 2015 - (ACN Newswire) - Advanced Care Scripts (ACS), a leading specialty pharmacy and clinical services platform of Omnicare Specialty Care Group (SCG), is proud to be part of the limited distribution network for the Novartis drug Farydak(R) (panobinostat).
The US Food and Drug Administration (FDA) recently approved Farydak(R) capsules in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory (IMiD) agent.
Multiple myeloma is an incurable blood cancer, and there is an urgent need for new treatments. Farydak is approved under FDA's accelerated approval program; regulatory applications are underway in the EU, Japan and worldwide. "We look forward to providing our clinical services expertise in oncology to patients prescribed this treatment option, and appreciate the opportunity to be part of this limited distribution network," said Dennis Wilson, VP & General Manager of Advanced Care Scripts.
Farydak has been shown to extend the progression-free survival (PFS) benefit of the standard-of-care therapy in this patient population. Farydak is approved under an accelerated approval based on PFS. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. The FDA's accelerated approval program gives patients access to treatments for serious or life-threatening illnesses that provide meaningful therapeutic benefit over existing treatments. The FDA has approved a risk evaluation and mitigation strategy (REMS) for Farydak. The REMS program serves to inform and educate healthcare professionals about the risks that may be associated with Farydak treatment.
The goal of Advanced Care Scripts is to remove barriers to access and increase speed to therapy. ACS has proven experience in successfully managing and dispensing specialty medications, such as Farydak, and related clinical services to improve adherence to therapy and patient outcomes.
About Omnicare Specialty Care Group
Omnicare Specialty Care Group (SCG) is a division of Omnicare, Inc., a Fortune 500 company and provider of comprehensive pharmaceutical services based in Cincinnati, Ohio. Omnicare SCG is a combination of synergistic tenured companies with a focused approach to pharmaceutical brand solutions. Together, Omnicare SCG brings specialists in reimbursement methods, clinicians practiced in medication therapy management for chronic disease states, and distribution channel expertise. Solutions are tailored to drive product access by solving challenges faced by patients and their caregivers, physicians, payers and manufacturers. Custom programs are led by a single management team across the organizational platforms, allowing coordination of resources and assets to support positive outcomes for our patients. For more information, visit www.omnicarescg.com.
About Advanced Care Scripts
Advanced Care Scripts, a specialty pharmacy, manages and dispenses specialty medications and products nationwide. It coordinates services beginning with the prescriber to simplify reimbursement and delivery of biotech therapies used to treat cancer, infectious diseases, auto-immune disorders, multiple sclerosis, hemophilia, and other disease states. Its customer service and comprehensive patient care model provides compliance and adherence support and cost-effective solutions for all classes of specialty medications.
Contact:
Patrick C. Lee
+1-513-719-1507
patrick.lee@omnicare.com
###
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Omnicare via Globenewswire
Topic: Press release summary
Source: Omnicare
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
